Member Info for TorquayFan

Rigga no - we prefer to observe from a quiet spot, for an hour or two, enjoying the fray, (with a glass of beer in hand). On Wednesday evening, the town was gridlocked with pick ups fully loaded with water butts and soaked revelers. It's a fun time but no guns for me. ATB

Answer IMHO no !
But in the middle of Songkran - even I can tell it's only Thursday Allan! So don't sell tomorrow. ATB

Konar 10.43 post. Highly recommended. A little optimism is not misplaced and the 'cold water pouring' doesn't rest well. The consensus Konar mentions is precisely put.

Vulpes report WILL be honest and not contrived to support the SP. IMO 100% Quite how would they explain that later ?

https://www.youtube.com/watch?v=CIMNXogXnvE&ab_channel=IanDury%26TheBlockheads

Happy to see the buying resume today - the science will see us through. IMO

Vulpes believe in Scancell and so do I. GLA

An email today - "AACR Annual Meeting 2023 - We are pleased to share that Cancer Grand Challenges will be at the AACR Annual Meeting 2023 in Orlando, Florida this week. If you’re attending, come and see us at stand 707 to discover our nine new challenges and $25m funding opportunity.

Our founders will also be at the conference – visit Cancer Research UK at stand 1023 and the National Cancer Institute at stand 809. We’re inviting international teams to come together, think differently and take on one of our new challenges."

Are CRUK going to find themselves out of the Scancell 'loop'? I think so. Anyway - money well spent by them I'm sure . . . .

MMmmm it seems to me that might be important. Thanks Johnny.

Ivy thanks - yes I did, as Crumbs posted - "those articles are basically adverts for the mRNA route and in particular the so far leaders in it -Moderna and BioNTech".

But if the Modi 1 trial produces good data, it seems Scancell will have the 'best in class, bar none'. Compared to which, Moderna and BioNTech's efforts might 'pale'.

16.75 pence - no way . . . . .

"'We’ve had to go longer and deeper, but when we get there it will be a bigger story because we will have achieved what nobody else has achieved and like everything when you’re the first it’s tougher."

Thanks for that RW - words that I'm sure we all remember BUT it is really good good to see them again !

If the Modi 1 trial produces good data, it seems Scancell will have the 'best in class, bar none.

Yes - got it in one ! See you Tuesday . . . .

I've been wondering why it's so quiet ! Dooh.
Wishing you all a happy Easter weekend . . . . .

Yes Ivy - exactly. 'Just for fun'. But it's surprising to me that CEPI have done no follow up about Scancell, at all, since Mar 2021, on their beautiful website. ATB

Ooops the theme of the CEPI day was : "How climate change increases pandemic risk" https://endpandemics.cepi.net/climate-change/ moving onto the rest.

"Investing now in boosting global disease surveillance and early warning systems, as outlined in the 100 Days Mission, and in scientific research to prepare for known and as-yet-unknown epidemic diseases, will mean that—just like with climate change—we can begin to cap the rising risks, turn the tide of threats, and eventually neutralise their pandemic potential."

Let's hope CEPI find a way to advance that !

Arriving by email this morning, this link 'The Urgency of Now' in respect of finding vaccines for the NEXT pandemic ! https://endpandemics.cepi.net/climate-change/

And still tucked deep away in the anals of CEPI - https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/

". . . . scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses."

A search reveals no other mention of Scancell/Covidity since this piece in March 2021.

A brilliant website IMO but as for CEPI - no follow up? No update? No interest? No cash? One wonders what the point is of CEPI?

Well said Berm. Good luck Richard !

Yes it's Non Exec and he's been a Consultant since 2021. Good luck to him.

From Marcus https://sisaf.com/news/richard-goodfellow-joins-sisaf-board-of-directors/

Crikey GF ! He can't stop working !
Is that Non-Exec ?

OK thanks C11 - I guess well have to wait and see. I honestly have no idea how these 'Meets' work. ATB

Johnny thanks - so Prof. O will be talking about Modi 1 too ! Good!

If results/preliminary data cannot be included in the Abstract, providing they have been announced and publicised earlier, they can surely be made available at AACR to those who show interest ?

GLA

Johnny thanks for that. Seeing this in simple terms (as I do), Prof. O will be there for Transgene I suppose - lets hope in the Q and A session - he has some freedom to talk a little more widely ? ATB

Crumbs going back to your 11.48 - "TCR research collab has lasted so long is also indicative of their continued interest and support..." - well yes but also as BioNTech have been involved so long, they must know all there is to know by now about that Scancell science but still no commercial moves from them?

Perhaps BioNTech are in their own tunnel and as you say, "obviously any deal/s done with them will only be for their own pipeline interests". I'd say 'probably' there rather than 'obviously'.

There must be a massive hole in BioNTech's earnings after Covid and yet 'Covidity' remains 'on shelf' ?

Any deal done with BioNTech would be great - but I'm not optimistic in that direction. However I would very much enjoy being totally wrong ! ATB

Cleaner thanks - that Genmab/BioNTech cooperation was dated August 2022 which predates Genmab's deal with Scancell in October 2022.

It's hard to know how this might tie in.